Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short term Debt (2018 - 2025)

China SXT Pharmaceuticals has reported Short term Debt over the past 8 years, most recently at $8781.0 for Q1 2025.

  • For Q1 2025, Short term Debt fell 98.22% year-over-year to $8781.0; the TTM value through Mar 2025 reached $8781.0, down 98.22%, while the annual FY2025 figure was $8781.0, 98.22% down from the prior year.
  • Short term Debt for Q1 2025 was $8781.0 at China SXT Pharmaceuticals, down from $7.4 million in the prior quarter.
  • Over five years, Short term Debt peaked at $12.1 million in Q1 2021 and troughed at $8781.0 in Q1 2025.
  • A 5-year average of $2.9 million and a median of $457111.0 in 2023 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: tumbled 99.91% in 2022 and later skyrocketed 1668.2% in 2024.
  • Year by year, Short term Debt stood at $2.1 million in 2021, then plummeted by 99.46% to $11404.0 in 2022, then soared by 3593.16% to $421168.0 in 2023, then skyrocketed by 1668.2% to $7.4 million in 2024, then crashed by 99.88% to $8781.0 in 2025.
  • Business Quant data shows Short term Debt for SXTC at $8781.0 in Q1 2025, $7.4 million in Q3 2024, and $493054.0 in Q1 2024.